Omya will present its active pharmaceutical ingredients Omyapure® and Omya-Cal®, natural calcium carbonates for dietary supplements, antacids and osteoporosis treatments at the CPhI.
Omyapharm® 500-OG is a fine powder consisting of calcium carbonate and tribasic calcium phosphate. It is suitable for wet and dry granulation as well as for hot-melt extrusion. Omyapharm® 500-DG OG, meanwhile, is the granulated form of Omyapharm® 500-OG and contains a superdisintegrant. Thanks to its special granulation, Omyapharm® 500-DG OG offers improved flowability and can be directly compressed into tablets.
Omyapharm® 500-DG OG has special importance when it comes to orally dispersible tablets (ODTs) and granules (ODGs). Its high porosity and specific surface properties enable fast disintegration and excellent compactibility that results in harder tablets at low compression forces. Tablets formulated with the functionalized calcium carbonate can be filled in conventional packaging because of their mechanical strength, thus reducing costs and difficulties during the conditioning process. ODTs manufactured from this excipient disintegrate in less than ten seconds. At Omya’s booth, CPhI visitors will be able to see flavored ODT samples and experience their fast disintegration properties first hand.
Omya will also showcase its natural calcium carbonates Omyapure® and Omya-Cal®. Natural calcium carbonate is a high purity calcium source with 40 percent bioavailable calcium. This makes it a valuable ingredient for calcium supplementation – for instance, to treat conditions such as osteoporosis – and for antacid formulations to neutralize stomach acid.
Thanks to their comprehensive formulation know-how, the company’s experts are able to develop tailor-made formulations in response to specific customer needs.
By Martin de Vries|2020-05-08T19:32:05+02:0012-07-2017|News|Comments Off on Omya will present its active pharmaceutical ingredients Omyapure® and Omya-Cal®, natural calcium carbonates for dietary supplements, antacids and osteoporosis treatments at the CPhI.